Episode to Feature Beverly Hills Plastic
Surgeon Dr. Charles J. Galanis Performing
Renuvion's Minimally Invasive Neck Procedure on
Patient
CLEARWATER, Fla., Feb. 9, 2023
/PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX),
the manufacturer of the proprietary helium plasma and
radiofrequency technology marketed and sold as
Renuvion®, today announced that "The Balancing Act''
television show on Lifetime® will broadcast
a segment nationally on the Renuvion neck laxity procedure on
Monday, February 13, at 7:30am (ET/PT).
The story will feature video footage of the minimally invasive,
one-hour neck procedure performed by double board-certified plastic
surgeon Dr. Charles J.
Galanis, of Galanis Plastic Surgery in Beverly Hills, CA, on patient Shelley
C., a 56-year-old mother of two from Rancho Palos Verdes, CA. An in-studio
interview by the show's co-host, Montel
Williams, with Dr. Galanis will occur to discuss this
revolutionary procedure with Renuvion to correct a sagging 'turkey
neck' and reveal the "astounding" results on air.
Now in its 20th season, "The Balancing Act" is a
daily talk show that airs weekday mornings on Lifetime and
targets women who do-it-all. The show aspires to provide its
audience with helpful tips and tricks to guide them through
parenting, personal and work lives. Co-hosts Montel Williams, Olga
Villaverde, Julie Moran and
Chef Ralph Pagano discuss topics
that help women find balance between home and family, work and
relationships. Each day's episode has a different theme -- Mondays
are focused on self-improvement.
The only minimally invasive product cleared by the FDA to
improve the appearance of loose skin on the neck and chin, Renuvion
offers patients a cost-effective and minimal downtime option. The
results reveal a more contoured appearance, including a tauter
neckline with smoother skin, and the results will continue to
improve over time. Renuvion is fast becoming a hot topic in media
surrounding plastic surgery; it was also recently featured in the
hit E! television series "Botched" as well as The
Learning Channel (TLC) series "Awake Surgery" for cosmetic
procedures.
"I've always been physically fit and healthy but started
noticing that my neck looks droopy in pictures," said Shelley. "I
started researching various treatments other than plastic surgery
with the hopes of finding something that was minimally invasive,
and that's how I found out about Renuvion. I saw that Dr. Galanis
has been doing this for quite a while, so upon consulting with him
and seeing his patient results, I knew this procedure would be the
ideal way for me to go".
"Shelly's a great candidate for Renuvion because she exhibits
some of those early signs of aging when people have a little bit of
that skin that's getting lax along the jowls and the neck area,"
said Dr. Galanis. "She's interested in something that provides more
of a natural aesthetic in terms of an outcome. Nothing that's too
drastic or too pulled like you might see with a facelift. And she's
at that age where it's an appropriate bridge prior to going under
the knife for a surgical option."
"The reason I like Renuvion for my patients is that for years
we've been looking in the world of plastic surgery at ways to
deliver results without putting people under the knife," said Dr.
Galanis. "There's really been a strong push towards what we call
minimally invasive techniques, and anytime we can capture a
population and maybe spare them surgery that's where something like
Renuvion is perfect. It fills the need to give people something as
a means of contracting the tissue without the surgical
excisions."
The Renuvion segment will re-run on "The Balancing Act" on
Lifetime on February 21 and
then have multiple re-broadcasts in syndication throughout
2023.
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology
company with a passion for elevating people's lives through
innovative products, including its Helium Plasma Technology
products marketed and sold as Renuvion® in the cosmetic
surgery market and J-Plasma® in the hospital
surgical market. Renuvion® and
J-Plasma® offer surgeons a unique ability to
provide controlled heat to tissue to achieve their desired results.
The Company also leverages its deep expertise and decades of
experience in unique waveforms through OEM agreements with other
medical device manufacturers. For further information about the
Company and its products, please refer to the Apyx Medical
Corporation website at www.ApyxMedical.com.
About The Balancing Act:
The Balancing Act is a morning show created and produced by
BrandStar that offers sensible solutions and essential
information in a fun, entertaining format; providing resources to
help people do life better. The Balancing Act features everything
from delicious recipes, style makeovers and dream getaways to
parenting tips and the latest news in health and wealth. Tune in to
The Balancing Act weekdays at 7:30 a.m.
(ET/PT) on Lifetime® and find all previously
aired episodes on TheBalancingAct.com.
Cautionary Statement on
Forward-Looking Statements
Certain matters discussed in this release and oral statements
made from time to time by representatives of the Company may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and the Federal
securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
All statements other than statements of historical fact are
statements that could be deemed forward-looking statements,
including but not limited to, any statements regarding the
potential impact of the COVID-19 pandemic and the actions by
governments, businesses and individuals in response to the
situation; projections of net revenue, margins, expenses, net
earnings, net earnings per share, or other financial items;
projections or assumptions concerning the possible receipt by the
Company of any regulatory approvals from any government agency or
instrumentality including but not limited to the U.S. Food and Drug
Administration, supply chain disruptions, component shortages,
manufacturing disruptions or logistics challenges; or macroeconomic
or geopolitical matters and the impact of those matters on the
Company's financial performance.
Forward-looking statements and information are subject to
certain risks, trends and uncertainties that could cause actual
results to differ materially from those projected. Many of these
factors are beyond the Company's ability to control or predict.
Important factors that may cause the Company's actual results to
differ materially and that could impact the Company and the
statements contained in this release include but are not limited to
risks, uncertainties and assumptions relating to the regulatory
environment in which the Company is subject to, including the
Company's ability to gain requisite approvals for its products from
the U.S. Food and Drug Administration and other governmental and
regulatory bodies, both domestically and internationally; the
impact of the recent FDA Safety Communication on our business and
operations; factors relating to the effects of the COVID-19
pandemic; sudden or extreme volatility in commodity prices and
availability, including supply chain disruptions; changes in
general economic, business or demographic conditions or trends;
changes in and effects of the geopolitical environment; liabilities
and costs which the Company may incur from pending or threatened
litigations, claims, disputes or investigations; and other risks
that are described in the Company's Annual Report on Form 10-K for
the fiscal year ended December 31,
2021 and the Company's other filings with the Securities and
Exchange Commission. For forward-looking statements in this
release, the Company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The Company assumes no obligation to
update or supplement any forward-looking statements whether as a
result of new information, future events or otherwise.
Media Contact:
Jane Sparango
Coterie Media (for Renuvion)
jane@coteriemedia.com
310-339-1214
Investor Relations Contact:
ICR Westwicke on behalf of Apyx Medical Corporation
Mike Piccinino, CFA
investor.relations@apyxmedical.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/renuvion-cosmetic-neck-laxity-procedure-to-be-featured-on-the-balancing-act-talk-show-on-lifetime-february-13-301742638.html
SOURCE Renuvion